Abstract
Get full access to this article
View all access options for this article.
References
1.Astellas Pharma and Audentes Therapeutics. Astellas enters into definitive agreement to acquire Audentes therapeutics . 2019. http://investors.audentestx.com/news-releases/news-release-details/astellas-enters-definitive-agreement-acquire-audentes (last accessed
December 7 , 2019
).
2.
Schwartz
JP
,
Ha
DG
,
Park
J
. Astellas picks a stellar acquisition target in BOLD. SVB Leerink, December 2, 2019. https://portal.svbleerink.com/IRPDocumentViewer/Web/DocumentViewerCache.aspx?docId=4355435847616E2B365867422B364D6B662B7A6E79673D3D&pad=4D306C715937356D532F6566637573516475422F78513D3D&userId=6B546A444D51694B394F595639434A6D314E652F79413D3D (last accessed
December 7 , 2019
).
3.
Thermo Fisher Scientific, Inc. Thermo Fisher Scientific opens $90 million viral vector manufacturing site in Massachusetts. 2019. http://thermofisher.mediaroom.com/2019-12-04-Thermo-Fisher-Scientific-Opens-90-Million-Viral-Vector-Manufacturing-Site-in-Massachusetts (last accessed December 8, 2019).
4.
Bollea L. Thermo Fisher Scientific unveils $6 million expansion at viral vector manufacturing facility. 2019. https://patheon.com/wp-content/uploads/Alachua-FL-Expansion.pdf (last accessed December 8, 2019).
5.Harvard University . New center for innovating and manufacturing next-generation medicines planned for metro Boston. November 25, 2019. https://www.harvard.edu/media-relations/new-center-for-innovating-and-manufacturing-next-generation-medicines-planned-for (last accessed
December 8 , 2019
).
6.FUJIFILM Diosynth . https://fujifilmdiosynth.com/resource/fujifilm-diosynth-biotechnologies-announces-55-million-usd-investment-to-expand-gene-therapy-development-capabilities/ (last accessed
December 8 , 2019
).
7.Fujifilm Corporation. Fujifilm announces expansion of its biopharmaceutical contract development and manufacturing business . 2019. https://www.fujifilm.com/news/n191114.html (last accessed
December 8 , 2019
).
8.bluebird bio, Inc. bluebird bio Presents New Data from Ongoing Phase 1/2 HGB-206 Study of LentiGlobin™ Gene Therapy for Sickle Cell Disease (SCD) at 61st ASH Annual Meeting and Exposition. 2019. http://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-presents-new-data-ongoing-phase-12-hgb-206-study (last accessed December 8, 2019).
9.bluebird bio, Inc. A study evaluating the safety and efficacy of the LentiGlobin BB305 drug product in severe sickle cell disease. 2019. https://clinicaltrials.gov/ct2/show/NCT02140554 (last accessed December 8, 2019).